Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1884 • ACR Convergence 2025
The Importance of Adherence to Dietary Recommendations for Rheumatoid Arthritis Risk May Be Greater in Younger Individuals – Results from a Nested Case-Control Study
Rebecka Bäcklund¹, Ulf Bergström¹, Michele Compagno¹, Linnea arvidsson², Emil Rydell³, Emily Sonestedt¹ and Carl Turesson³, ¹Lund University, Malmö, Sweden, ²Lund University, Malmö, ³Lund University, Malmö, Sweden
Background/Purpose: Healthy eating habits might prevent the development of rheumatoid arthritis (RA). The impact of such lifestyle factors on the risk of RA may differ…
Abstract Number: 1701 • ACR Convergence 2025
Gene Editing of HLA-Class II DRB1*04:01 at Position 82 Abrogates Binding of Citrullinated Arthritogenic Peptides and Collagen
Vibha Jha¹, Brian Freed², Niyun Jin¹, Manjula Miglani¹ and Christina Roark², ¹University of Colorado, Aurora, CO, ²Clinimmune Labs Immunology, School of Medicine, Aurora, CO
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease with a strong genetic association to Class II HLA-DRB1*04:01. Presentation of arthritogenic peptides bound to DRB1*04:01…
Abstract Number: 1646 • ACR Convergence 2025
The Obesity Paradox in Rheumatoid Arthritis: A Propensity-Matched Analysis of Mortality and Cardiovascular Outcomes
Queeneth Edwards¹, Chukwuemelie Okeke², Justin Riley³, Ufuoma Mamoh⁴ and Chekwube Obianyo⁵, ¹Georgia Southern University, Statesboro, GA, ²Maimonides Medical Center, Brooklyn, NY, ³Jefferson Einstein Hospital Philadelphia, Philadelphia, PA, ⁴Medstar Health Georgetown University Internal Medicine Residency Program, Baltimore, MD, ⁵Georgia Southern University, statesboro
Background/Purpose: Obesity is traditionally associated with increased morbidity and mortality in the general population. However, in chronic inflammatory conditions like rheumatoid arthritis (RA), an "obesity…
Abstract Number: 1361 • ACR Convergence 2025
Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Mingfang Sun¹, Xue Chen², Ying Zhou², Yanlong Yang², Fei Xiao² and huanzi dai², ¹Daping Hospital, chongqing, China (People's Republic), ²Daping Hospital & Research Institute of Surgery, Army Medical University, Chongqing, PR China., Chongqing, China (People's Republic)
Background/Purpose: Connective tissue disease-associated interstitial lung disease(CTD-ILD) represents a significant cause of mortality among patients. Presently, research on treatment options for CTD-ILD is limited, with…
Abstract Number: 1344 • ACR Convergence 2025
Exploring the Factors Associated with the Discontinuation of Tofacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
yao fan fang¹, Ping-Han Tsai² and yen Fu CHEN³, ¹Chang Gung memorial hopspital, Linkou, Taipei, New Taipei, Taiwan (Republic of China), ²Chang Gung memorial hospital, linkou, Taipei, Taiwan (Republic of China), ³Chang Gung memoriial hospital linkou, taipei, Taiwan (Republic of China)
Background/Purpose: Tofacitinib is the first oral targeted synthetic disease-modify anti-rheumatic drug for patients with moderate to severe rheumatoid arthritis 1. This study aimed to identify…
Abstract Number: 1327 • ACR Convergence 2025
Systematic Review of Mobility in Rheumatoid Arthritis with Digitally Measured Objective Assessment
Anna fishbein¹, Rachel Lawson², Veleka Allen¹, Xiaozhong Zhang³, Laura Chambre⁴, Stephen Ruhmel¹, Sophie Wilhelm¹, Fredric Marrache⁵, Maria Wiekowski¹, Markus Kohlmann⁶ and Jeffrey Curtis⁷, ¹Sanofi, Morristown, NJ, ²Sanofi, Earley, United Kingdom, ³Sanofi, Chengdu, China (People's Republic), ⁴Sanofi, Cambridge, MA, ⁵Sanofi, Gentilly, France, ⁶Sanofi, Frankfurt, Germany, ⁷University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Patients with rheumatoid arthritis (RA) are less physically active than the general population, and these activity differences can be measured through digital devices. This…
Abstract Number: 1310 • ACR Convergence 2025
Naturalized Language Processing Based Extraction of Rheumatoid Arthritis Disease Activity Measures from the Electronic Health Record
Elizabeth Park¹, Iram Kamdar², Reid Weisberg¹, Andy Nguyen¹, Joan Bathon³, Jon Giles⁴, Chunhua Weng⁵ and Elana Bernstein¹, ¹Columbia University Irving Medical Center, New York, NY, ²Columbia University Data Science Institute, New York, NY, ³Columbia University, NEW YORK, NY, ⁴Cedars-Sinai Medical Center, New York, NY, ⁵Columbia University Department of Biomedical Informatics, New York, NY
Background/Purpose: A treat-to-target approach in rheumatoid arthritis (RA) requires intense monitoring of RA disease activity with measures such as the clinical disease activity index (CDAI).…
Abstract Number: 1199 • ACR Convergence 2025
Interstitial Lung Disease in Systemic Autoimmune Rheumatic Diseases (SARDs): Radiologic and Histologic Correlations
Darya S. Jalaledin¹, Aidan pye², Angela Chang², Navid Saleh², Saud AlHajeri³, Beatrice Daviault⁴, Arusa Shah⁵, Sabrina Hoa⁶, Océane Landon-Cardinal⁷, Alec Yu², Robert Levy⁸, Jennifer Wilson⁹, Charles Poirier⁴, James Choi², John Yee², Hyein Kim² and Kun Huang¹⁰, ¹Université de Montréal, Saint-Lambert, QC, Canada, ²University of British Columbia, VANCOUVER, BC, Canada, ³University of British Columbia, Vancouver, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵University of Montreal, Montreal, BC, Canada, ⁶University of Montreal, Brossard, QC, Canada, ⁷Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁸University of British Columbia, Deerfield, IL, ⁹UBC, Vancouver, BC, Canada, ¹⁰University of British Columbia, Vancouver, Surrey, BC, Canada
Background/Purpose: Systemic autoimmune rheumatic diseases (SARDs) are a major cause of interstitial lung disease (ILD), with high prevalence in inflammatory idiopathic myopathy (IIM), systemic sclerosis…
Abstract Number: 1041 • ACR Convergence 2025
Associated Factors And Direct Cost Analysis Of Dose Reduction And Discontinuation Of Biological Therapies In Rheumatoid Arthritis And Spondyloarthritis: Findings From A Colombian Cohort Within The Framework Of An Integrated Management Model
Edwin Jauregui¹, Deisy Restrepo², Belcy Garzon², Alexis Atuesta², Nestor Correa², Jessica Barrera² and Andrea Rubio², ¹Riesgo de fractura S.A, Bogotá, Colombia, ²Riesgo de fractura S.A, Bogotá, Colombia
Background/Purpose: Dose reduction of biologic therapy (BT) in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA) has been increasingly implemented in recent years, in accordance…
Abstract Number: 0988 • ACR Convergence 2025
Distinct Effects of Inhibitory Receptor Agonism on RA Synovial CD4+ T Cell Functions
Kazuhiko Higashioka¹, John Sowerby¹, Kathryne Marks², Diana Pena-Nunez¹, Margaret Chang³, Jonathan Coblyn¹, Elena Massarotti¹, Brian Jones⁴, Ling-Yang Hao⁴, Navin Rao⁴ and Deepak Rao², ¹Brigham and Women's Hospital, Boston, ²Brigham and Women's Hospital, Boston, MA, ³Boston Children's Hospital, Boston, MA, ⁴Janssen Research & Development, Spring House
Background/Purpose: Autoreactive T cells play a crucial role in the autoimmune pathology of rheumatoid arthritis (RA). Activation of inhibitory receptors on T cells is a…
Abstract Number: 0872 • ACR Convergence 2025
Silencing of Schnurri-3 protects from TNF-induced bone loss and is accompanied by upregulation of type I Interferon-Stimulated Genes (ISGs) in osteoblasts.
Priyanka Kushwaha¹, Albert Tai², Catherine Manning³, Yeon Suk Yang⁴, Jae-Hyuck Shim⁴ and Ellen M. Gravallese⁵, ¹Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, ²Department of Immunology, Tufts University School of Medicine, Boston, MA, ³Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁴²Department of Medicine/Division of Rheumatology, University of Massachusetts Chan Medical School, Worcester, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: Schnurri-3 (SHN3) is an adaptor protein and a negative regulator of osteoblast (OB) function. Its inhibition prevents bone loss and joint erosion in models…
Abstract Number: 0798 • ACR Convergence 2025
Inhibition of Wnt Signaling Attenuates Inflammatory Arthritis Severity
Alisa Mueller¹, Angela Zou², Lucy-Jayne Marsh³, Samuel Kemble³, Saba Nayar³, Gerald Watts⁴, Cassandra Murphy⁵, Emily Taylor³, Triin Major³, David Gardner⁶, Christopher Buckley⁷, Kevin Wei⁸, Soumya Raychaudhuri⁵, ilya Korsunsky⁵, Andrew Filer⁹, Adam Croft¹⁰ and Michael Brenner¹¹, ¹Stanford University and VA Palo Alto Health Care System, Stanford, CA, ²Harvard Medical School, Boston, MA, ³University of Birmingham, Birmingham, United Kingdom, ⁴Harvard Medical School, Brookline, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶University of Birmingham, Havelock North, New Zealand, ⁷University of Oxford, Oxford, United Kingdom, ⁸Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁹The University of Birmingham, Birmingham, United Kingdom, ¹⁰University of Birmingham, Hagley, Stourbridge, United Kingdom, ¹¹Brigham and Women's Hospital, Harvard Medical School, Newton, MA
Background/Purpose: Fibroblasts are critical in promoting pathogenic synovial inflammation and bone erosion in rheumatoid arthritis (RA). Moreover, recent studies have pointed to their potential contribution…
Abstract Number: 0496 • ACR Convergence 2025
Certolizumab Pegol Shows a Higher Retention Rate Compared to JAK Inhibitors in Patients with Rheumatoid Arthritis, Regardless of Baseline Rheumatoid Factor Levels. A Multicenter Retrospective Study.
Mitndbaim Parra¹, Rafaela Ortega-Castro², Jerusalén Calvo³, Francisco Jose Cepas⁴, Montserrat Robustillo-Villarino⁵, Andres Zuniga-Vera⁵, Ana Martinez-Feito⁶, Chamaida Plasencia-Rodríguez⁷, Ester Costa-Moya⁸, Delia Taverner-Torrent⁸, Luis Sainz Comas⁹, Cesar Diaz-Torne⁹, Virginia Ruiz-Esquide¹⁰, Cynthia Rojas¹¹, Lourdes Martin-de la Sierra Lopez¹², Laura Jimenez-Rodriguez¹², David Velasco-Sanchez¹², Regina Fará Garcia¹³, Antonio Juan-Mas¹⁴, Marina soledad Moreno Garcia¹⁵, Ana Valeria Acosta Alfaro¹⁶, Santiago Muñoz¹⁷, Maria Martín López¹⁸, Raquel Zas¹⁹, FRANCISCO JAVIER GODOY NAVARRETE²⁰, Isabel Anon Onate²¹, Fernando Ortiz-Márquez²², Natalia Mena Vázquez²³, Paula Estrada-Alarcón²⁴, Lourdes Ladehesa²⁵, Alejandro Escudero Contreras³ and Clementina López Medina²⁶, ¹¹. Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., Cordoba, Spain, ²Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ³IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁴University of Cordoba, Cordoba, Spain, ⁵Department of Rheumatology, Hospital Universitario de la Plana, Vila-real, Castellón, Spain, Vila-real, Castellón, Spain, ⁶Hospital Universitario La Paz, Madrid, Madrid, Spain, ⁷Hospital Universitario La Paz, MADRID, Spain, ⁸Hospital Sant Joan Reus, Reus, Spain, ⁹Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, ¹¹Hospital Clinic, Barcelona, Spain, ¹²Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ¹³Hospital Son Llàtzer, Palma, Spain, ¹⁴Son Llazter University Hospital, Madrid, Spain, ¹⁵Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁶Hospital Universitario Infanta Sofia; Universidad Europea de Madrid; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁷Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, Madrid, Spain, ¹⁸Hospital ¹² de Octubre, Madrid, Spain, ¹⁹Hospital Universitario Doce de Octubre, Madrid, Spain, ²⁰Jaen University Hospital, Spain, Jaen, Spain, ²¹Hospital Universitario de Jaén, Jaén, Spain, ²²Department of Rheumatology, Hospital Regional Universitario de Málaga, Málaga, Spain, Malaga, Spain, ²³Hospital Regional Universitario de Malaga, Malaga, Spain, Málaga, Spain, ²⁴Hospital de San Juan Despí Moisès Broggi, Barcelona, Spain, ²⁵IMIBIC-Reina Sofia Hospital-University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²⁶Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Rheumatoid factor (RF) is an antibody directed against the Fc fragment of IgG that plays a key role in the development of rheumatoid arthritis…
Abstract Number: 0479 • ACR Convergence 2025
Risk of Arrhythmias Following IL-6 Inhibitor Use; A Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS)
Asim Khanfar¹, Omar Hamdan², Shiamak Cooper³, Sanjana Thimmannagari¹ and Anthony Ocon⁴, ¹Rochester General Hospital, Rochester, NY, ²University of Jordan, Az-Zarqa, Jordan, ³Rochester General Hospital, Irondequoit, NY, ⁴Rochester Regional Health, Fairport, NY
Background/Purpose: Interleukin-6 (IL-6) inhibitors, including tocilizumab and sarilumab, are immunomodulatory agents commonly used in the treatment of rheumatoid arthritis and COVID-19. Prior studies have implicated…
Abstract Number: 0464 • ACR Convergence 2025
Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty
Solana Cushing¹, Kelsey Gripp², Edward DiCarlo³, Deanna Jannat-Khah¹, Yoshimi Endo³, Jose Rodriguez³, Mark Figgie³, Bella Mehta⁴ and Susan Goodman³, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Reoperations following arthroplasty are a significant burden to patients and surgeons. In patients with RA who receive total hip (THA) or knee (TKA) arthroplasty,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].